

Biosimilars Market - 2026-2035

<https://marketpublishers.com/r/BD30FA10C9A3EN.html>

Date: July 2026

Pages: 37

Price: US\$ 3,400.00 (Single User License)

ID: BD30FA10C9A3EN

Abstracts

Biosimilars Market reached US\$34.57 billion in 2025 and is expected to reach US\$ 129.29 billion by 2035, growing with a CAGR of 14.10% during the forecast period 2026-2035.

The Biosimilars Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Biosimilars Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Drug Class

Monoclonal Antibodies (mAbs)*

Tumor Necrosis Factor-Alpha (TNF-?) Inhibitors

Granulocyte Colony-Stimulating Factor (G-CSF)

Insulin

Erythropoietin

Human Growth Hormone

Follitropin

Interferons

Anti-Vascular Endothelial Growth Factor

Other Drug Classes

By Therapeutic Area

Oncology*

Immunology & Autoimmune Diseases

Metabolic Diseases (including diabetes)

Neurology

Infectious Diseases

Rare Diseases

Others

By Manufacturing Modality

Mammalian Cell-Based Biosimilars*

Microbial-Based Manufacturing

Plasma-Derived Manufacturing

Other Manufacturing Platforms

By Route of Administration

Intravenous *

Subcutaneous

Intramuscular

Others

By End-User

Hospitals & Specialty Clinics*

Infusion Centers

Specialty Pharmacies

Others

Regional Analysis for Biosimilars Market:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Africa)

This Report Covers:

Go-to-market Strategy.

Neutral perspective on the market performance.

Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

Customized regional/country reports as per request and country level analysis.

Potential & niche segments and regions exhibiting promising growth covered.

Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Biosimilars Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. DEFINITION AND OVERVIEW

- 1.1. Study Objectives
- 1.2. Market Definition
- 1.3. Market Scope
- 1.4. Stakeholder Analysis
- 1.5. Currency Considered
- 1.6. Study Period

2. EXECUTIVE SUMMARY

- 2.1. Key Takeaways
- 2.2. Top To Bottom Analysis
- 2.3. Market Share Analysis
- 2.4. Data Points from Key Primary Interviews
- 2.5. Data Points from Key Secondary Databases
- 2.6. Market Snapshot
- 2.7. Geographical Snapshot

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Government-Led Switching and Tender Policies Accelerating Biosimilars Adoption in Public Health Systems
 - 3.1.1.2. Patent Expiry Wave of Blockbuster Biologics Unlocking Multi-Billion-Dollar Biosimilars Entry Windows
 - 3.1.1.3. Hospital and Payer Cost-Containment Programs Prioritizing Biosimilars in Treatment Protocols
 - 3.1.2. Restraints
 - 3.1.2.1. Interchangeability and Physician Confidence Barriers Slowing Automatic Substitution
 - 3.1.2.2. High Analytical and Clinical Comparability Costs Limiting New Entrant Participation
 - 3.1.2.3. Complex Cold-Chain and Bioprocess Manufacturing Requirements Increasing Operational Risk
 - 3.1.3. Opportunity

3.1.3.1. Rapid Expansion of Biosimilars in Emerging Therapeutic Segments such as Ophthalmology and Rare Diseases

3.1.3.2. Strategic Licensing and Co-Development Agreements Between Innovators and Biosimilars Developers

3.1.3.3. Growth of Local Biomanufacturing Hubs in Asia and Latin America Supporting Export-Oriented Drug Class

3.1.4. Trends

3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

4.1. Porter's Five Force Analysis – Global Biosimilars

4.2. Geopolitical & Supply Chain Exposure

4.3. Social & Patient-Centric Factors

4.4. Economic Factors

4.5. Pricing Analysis

4.6. Regulatory Analysis

4.7. Go-To-Market (GTM) Strategy

4.8. Innovation & R&D Trends

4.9. Sustainability and ESG Analysis

4.10. Biosimilars Ecosystem Participants

4.11. Buyer Decision Criteria & Adoption Drivers

4.12. DMI Opinion – Strategic Outlook for the Global Biosimilars Market

5. BY DRUG CLASS

5.1. Introduction

5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

5.1.2. Market Attractiveness Index, By Drug Class

5.2. Monoclonal Antibodies (mAbs)*

5.2.1. Introduction

5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

5.3. Tumor Necrosis Factor-Alpha (TNF-?) Inhibitors

5.4. Granulocyte Colony-Stimulating Factor (G-CSF)

5.5. Insulin

5.6. Erythropoietin

5.7. Human Growth Hormone

5.8. Follitropin

5.9. Interferons

5.10. Anti-Vascular Endothelial Growth Factor

5.11. Other Drug Classes

6. BY THERAPEUTIC AREA

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area

6.1.2. Market Attractiveness Index, By Therapeutic Area

6.2. Oncology*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Immunology & Autoimmune Diseases

6.4. Metabolic Diseases (including diabetes)

6.5. Neurology

6.6. Infectious Diseases

6.7. Rare Diseases

6.8. Others

7. BY MANUFACTURING MODALITY

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality

7.1.2. Market Attractiveness Index, By Manufacturing Modality

7.2. Mammalian Cell-Based Biosimilars*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Microbial-Based Manufacturing

7.4. Plasma-Derived Manufacturing

7.5. Other Manufacturing Platforms

8. BY ROUTE OF ADMINISTRATION

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

8.1.2. Market Attractiveness Index, By Route of Administration

8.2. Intravenous *

8.2.1. Introduction

- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Subcutaneous
- 8.4. Intramuscular
- 8.5. Others

9. BY END-USER

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 9.1.2. Market Attractiveness Index, By End-User
- 9.2. Hospitals & Specialty Clinics*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Infusion Centers
- 9.4. Specialty Pharmacies
- 9.5. Others

10. BY REGION

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
 - 10.2.1. Introduction
 - 10.2.2. Key Region-Specific Dynamics
 - 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
 - 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
 - 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.2.8.1. US
 - 10.2.8.2. Canada
 - 10.2.8.3. Mexico
- 10.3. Europe
 - 10.3.1. Introduction
 - 10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality

10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area

10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.3.8.1. Germany

10.3.8.2. UK

10.3.8.3. France

10.3.8.4. Russia

10.3.8.5. Italy

10.3.8.6. Spain

10.3.8.7. Norway

10.3.8.8. Netherlands

10.3.8.9. Sweden

10.3.8.10. Denmark

10.3.8.11. Belgium

10.3.8.12. Switzerland

10.3.8.13. Austria

10.3.8.14. Poland

10.3.8.15. Finland

10.3.8.16. Rest of Europe

10.4. Latin America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality

10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area

10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.4.8.1. Brazil

10.4.8.2. Argentina

10.4.8.3. Rest of Latin America

10.5. Asia-Pacific

- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
- 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.5.8.1. China
 - 10.5.8.2. India
 - 10.5.8.3. Japan
 - 10.5.8.4. Australia
 - 10.5.8.5. South Korea
 - 10.5.8.6. New Zealand
 - 10.5.8.7. Indonesia
 - 10.5.8.8. Malaysia
 - 10.5.8.9. Philippines
 - 10.5.8.10. Singapore
 - 10.5.8.11. Thailand
 - 10.5.8.12. Vietnam
 - 10.5.8.13. Rest of Asia-Pacific
- 10.6. Middle East and Africa
 - 10.6.1. Introduction
 - 10.6.2. Key Region-Specific Dynamics
 - 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
 - 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing Modality
 - 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
 - 10.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 10.6.8.1. UAE
 - 10.6.8.2. Saudi Arabia
 - 10.6.8.3. South Africa
 - 10.6.8.4. Israel
 - 10.6.8.5. Egypt

- 10.6.8.6. Turkey
- 10.6.8.7. Qatar
- 10.6.8.8. Kuwait
- 10.6.8.9. Oman
- 10.6.8.10. Bahrain
- 10.6.8.11. Rest of Middle East and Africa

11. COMPETITIVE LANDSCAPE ANALYSIS

- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
- 11.4. Partner Identification Analysis
- 11.5. Investment & Funding Landscape
- 11.6. Strategic Alliances & Innovation Pipelines

12. COMPANY PROFILES

- 12.1. Pfizer, Inc.*
 - 12.1.1. Company Overview
 - 12.1.2. Product Portfolio
 - 12.1.3. Revenue Analysis
 - 12.1.4. Pricing Analysis
 - 12.1.5. SWOT Analysis
 - 12.1.6. Recent Developments
 - 12.1.6.1. Major Deals
 - 12.1.6.2. M&A
 - 12.1.6.3. Collaboration
 - 12.1.6.4. Acquisition
 - 12.1.6.5. Joint Ventures
 - 12.1.6.6. Innovations
 - 12.1.7. Recent News
 - 12.1.7.1. Events
 - 12.1.7.2. Conferences
 - 12.1.7.3. Symposia
 - 12.1.7.4. Webinars
- 12.2. Amgen Inc.
- 12.3. Novartis AG (Sandoz division)
- 12.4. Samsung Bioepis Co., Ltd.

- 12.5. Celltrion, Inc.
- 12.6. Biocon Limited
- 12.7. Viatris Inc.
- 12.8. Teva Pharmaceutical Industries Ltd.
- 12.9. Boehringer Ingelheim International GmbH
- 12.10. Merck KGaA
- 12.11. F. Hoffmann-La Roche Ltd.
- 12.12. Dr. Reddy's Laboratories Ltd.
- 12.13. STADA Arzneimittel AG
- 12.14. Fresenius Kabi AG
- 12.15. Apotex Inc. (LIST NOT EXHAUSTIVE)

13. GLOBAL BIOSIMILARS MARKET – RESEARCH METHODOLOGY

- 13.1. Research Data
 - 13.1.1. Secondary Data
 - 13.1.2. Primary Data
 - 13.1.3. CAGR Analysis
- 13.2. Market Size Estimation Methodology
 - 13.2.1. Bottom-Up Approach
 - 13.2.2. Top-Down Approach
- 13.3. Market Breakdown & Data Triangulation
- 13.4. Research Assumptions
- 13.5. Limitations

14. APPENDIX

- 14.1. About Us and Services
- 14.2. Contact Us

I would like to order

Product name: Biosimilars Market - 2026-2035

Product link: <https://marketpublishers.com/r/BD30FA10C9A3EN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BD30FA10C9A3EN.html>